查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853990

口服固態製劑契約製造市場（按劑型、治療領域、應用、階段和客戶類型分類）－2025-2032年全球預測

Oral Solid Dosage Contract Manufacturing Market by Form Type, Therapeutic Area, Application, Stage, Customer Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，口服固態製劑契約製造市場規模將達到 877 億美元，複合年成長率為 8.95%。

關鍵市場統計數據
基準年2024年 441.6億美元
預計年份：2025年 482億美元
預測年份 2032 877億美元
複合年成長率 (%) 8.95%

本書簡明扼要地全面介紹了當前影響口服固態製劑契約製造的動態因素及其對相關人員的戰略意義。

口服固體製劑契約製造產業處於藥物創新、複雜供應鏈和嚴格監管的交匯點，要求相關人員在保持敏捷性的同時，確保產品品質毫不妥協。本執行摘要概述了影響生產力計畫開發平臺的擴展和客戶需求的日益多樣化，藥物受託製造製造商正從單純的生產合作夥伴轉型為提供製劑專業知識、法規知識和生命週期管理支援的策略合作夥伴。

要了解這一格局，就需要清楚地理解產品形式和治療重點如何影響生產的複雜性，臨床和商業階段如何改變需求模式，以及從生物技術創新者到成熟的製藥公司和營養保健品製造商等不同類型的客戶如何影響服務期望。本導言確立了貫穿整個報告的分析視角：將技術能力評估與商業策略和供應鏈風險管理結合。它也強調了決策者必須採用以證據為基礎的外包方法，權衡專業化帶來的好處與供應商網路集中化和不斷變化的貿易政策所帶來的風險。本執行摘要的其餘部分將這些考慮轉化為採購、營運、監管事務和業務拓展等部門領導者可操作的見解。

分析正在重新定義受託製造產能、品質期望和夥伴關係模式的變革性技術、監管和供應鏈轉變。

口服固體製劑契約製造領域正經歷一系列變革時期的驅動力來自技術進步、監管要求以及不斷變化的客戶需求。連續生產和先進的製程控制系統正從試點檢驗走向成熟，最終成為經過驗證的生產路線，從而提高了產量並加強了對關鍵品質屬性的控制。同時，生產營運的數位化，包括電子批記錄、預測性維護和高級分析，正在徹底改變產能監控、偏差管理以及向監管機構提交證據的方式。這些技術驅動的改進正在催生新的夥伴關係模式，在這種模式下，製造商提供的不再是單一批次的生產名額，而是整合的開發和規模服務。

法律規範也在不斷發展，監管機構更加重視即時產品品質保證和生命週期數據，以證明產品的穩健性和可追溯性。這種監管力度的加強提升了整合資料生態系統的價值，並增強了能夠證明端到端品管能力的製造商的議價能力。此外，複雜配方和多顆粒技術的興起正在推動服務產品方面的技術差異化，並促使契約製造製造商有選擇地投資於專業能力。同時，客戶的期望也在改變：生技公司尋求敏捷、以研發為中心的合作夥伴；大型製藥公司優先考慮具有長期合作關係、合規且擁有成熟全球分銷能力的供應商；而營養保健品客戶則優先考慮成本效益和上市速度。這些因素的相互作用正在重新定義策略受託製造合作夥伴的意義，加速整合、能力專業化和聯合商業化模式的形成。

評估2025年美國關稅政策變化對採購、成本結構、供應鏈韌性和策略採購選擇的累積影響

美國推出的2025年關稅政策對口服固體製劑契約製造原料藥和某些資本設備的進口成本競爭力，迫使許多生產商及其客戶重新評估其供應商佈局和庫存策略。一些公司採取的直接應對措施包括：透過多元化採購管道、建立關鍵原料的庫存緩衝以及評估近岸外包和回流生產方案來降低跨境成本波動風險。然而，這些戰術性措施需要在營運成本實力和供應鏈彈性之間做出權衡。

除了採購之外，關稅引發的投入成本波動也影響配方開發和製程選擇等上游決策。各團隊越來越傾向於選擇能夠最大限度減少關稅敏感成分使用或允許在不影響穩定性或性能的前提下進行替代的配方和輔料組合。同時，受託製造製造商正在投資供應鏈映射和雙重籌資策略，以降低集中採購的風險。關稅也凸顯了物流最佳化、分類準確性和自由貿易區利用在控制到岸成本的戰略重要性。展望未來，營運韌性將不再僅依賴單一的成本優勢，而是更取決於能否將採購彈性、材料替代的法規遵循以及透明的供應商關係整合到一個連貫的風險緩解體系中。

細分市場主導的洞察揭示了產品形態、治療用途、應用、開發階段和客戶類型如何影響您整個合約受託製造業務的服務需求。

在口服固體製劑契約製造中，細分市場層面的動態變化對於理解需求促進因素和產能要求至關重要。膠囊分為硬膠囊和軟膠囊，顆粒分為即時釋和緩釋，丸劑分為包衣丸劑和多顆粒丸劑，藥片分為包衣片劑和非包衣片劑，因此需要採用不同的生產策略。這些劑型製劑形式因素決定了資本投資、分析測試的範圍以及穩定性試驗的複雜程度，進而影響哪些研發公司更適合進行研發，哪些公司更適合進行大規模商業性化生產。

抗感染疾病項目，包括抗生素和抗病毒藥物，通常強調快速放大生產規模和嚴格的效力控制；而針對高血脂症和高血壓的心血管藥物組合則需要緩釋和高穩定性。中樞神經系統治療需要低劑量精準製劑以及控制釋放憂鬱症和抗癲癇製劑；而消化器官系統治療，例如胃酸抑制劑和促動力藥，則需要考慮獨特的溶出度和生物製藥特性。腫瘤治療，無論是針對血液腫瘤或固態腫瘤，都需要專門的隔離措施、監管鏈計劃以及以病人安全為中心的品質系統。此外，臨床階段和商業化階段計劃之間的差異決定了靈活性和檢驗性之間的平衡。最後，客戶類型也會影響合作模式。生技公司通常需要客製化的開發支援和靈活的反應速度；營養保健品客戶優先考慮成本效益高的生產和快速上市；而製藥客戶則重視長期供應的可靠性和全球監管的協調性。這些細分為技術投資、商業性定位和夥伴關係關係設計與客戶特定需求的協調提供了一個框架。

區域戰略視角展現了美洲、歐洲、中東和非洲以及亞太地區的動態變化如何重塑製造業佈局、物流和監管格局。

每個地區的市場動態差異顯著，並影響製造佈局、監管策略和物流方面的策略選擇。在美洲，製造商受益於毗鄰大型商業市場和響應迅速的分銷網路，但也面臨嚴格的監管審查和競爭壓力，需要針對特定產品類別實現本地化生產。該地區通常是後期商業供應和項目的首選地，這些項目對上市時間和快速補貨能力要求極高，因此，該地區支撐著一種強調經過檢驗的大規模製造能力和先進品質系統的模式。

歐洲、中東和非洲地區是一個多元化的市場環境，監管環境各異，定價機制分散，因此需要先進的監管情報和靈活的分銷計劃。在該地區營運的製造商必須應對不同的核准途徑、不同的監管時間表以及影響臨床和商業批次生產地點的區域貿易協定。該地區的產能投資通常包括模組化設施和完善的藥物安全檢測基礎設施，以支持跨國上市和核准後的承諾。

亞太地區在製劑研發、成本優勢製造以及快速發展的分析和法規專業知識方面擁有強大的實力，仍然是研發階段工作和散裝生產的戰略中心。然而，該地區的企業必須權衡成本優勢與日益成長的品質保證、資料完整性和符合國際法規標準的期望。供應鏈韌性因素，包括港口吞吐能力和地緣政治風險，在亞太地區的採購決策和全球專案的庫存佈局選擇中發揮關鍵作用。

競爭情報：透過摘要領先合約製造公司的策略重點、能力投資和夥伴關係方式，來描述它們的特徵。

領先的合約研究公司憑藉著深厚的技術實力、全面的開發服務和可靠的監管記錄脫穎而出。領先的供應商會選擇性地投資於靈活的生產平台，這些平台能夠檢驗各種固態劑型的生產能力，同時保持嚴格的數據完整性和品質保證系統。他們通常將產能投資與配方最佳化、分析方法開發和穩定性研究等相關服務相結合，使客戶能夠順利地從臨床批次過渡到商業化生產，而無需重複的供應商交接。

高績效公司的另一個大標誌是其清晰明確的夥伴關係模式，這種模式將獎勵與客戶成功緊密結合。這些模式包括透明的成本結構、規模化生產的風險共用機制，以及諸如法規文件支援和序列化準備等附加價值服務。對數位化營運的投資，例如即時批次分析、整合品管系統和先進的供應鏈視覺化工具，也使領先企業區別於普通商品供應商。此外，那些為輔料、包裝和專用模具構建強大供應商生態系統的公司，更有能力應對市場波動，並提供可靠的前置作業時間。儘管策略併購和聯盟仍然是擴大產能的途徑，但最重要的競爭優勢仍然是：能夠大規模地提供可預測的質量，透過創新解決配方難題，並在產品生命週期內提供諮詢和支援。

為行業領導者提供切實可行的建議，以加快韌性建設、提高效率、抓住新的商機，並使營運與不斷變化的客戶和監管需求保持一致。

行業領導者可以透過制定一系列有針對性的營運和商業優先事項，將他們的觀點轉化為實際行動。首先，他們投資於模組化、靈活的生產平台，以支援膠囊、顆粒、丸劑和片劑生產之間的快速切換，同時保持有效的品管。同時，他們提升配方和分析服務，以支持從低劑量中樞神經系統製劑到需要特殊密閉和穩定性通訊協定的腫瘤製劑等複雜的治療領域。擁有這些能力將縮短研發週期，並提升他們作為長期夥伴關係夥伴的吸引力。

第二，我們將透過實施關鍵輔料的雙源籌資策略和利用短期庫存策略來增強採購和規劃中的供應鏈韌性，尤其針對對關稅敏感的投入品。我們將利用先進的採購分析和供應商績效監控來強化此策略，以便及早發現並消除漏洞。第三，我們將優先投資於監管和資料完整性的改進，以促進跨國申報和即時品質監控，包括增強電子批次記錄、序列化和監管文件編制能力。第四，我們將最佳化商業性服務，包括基於績效的夥伴關係模式和整合從研發到商業化的過渡服務，從而協調獎勵並減少客戶摩擦。最後，我們將制定數位轉型藍圖，將生產分析、預測性維護和品質指標與經營團隊儀錶板連接起來。

詳細的調查方法，包括一手和二手檢驗、同行驗證、品管以及分析框架，以確保嚴謹的洞察力和可重複性。

本執行摘要的調查方法整合了多個資料流和檢驗通訊協定，以確保分析的嚴謹性和實際應用價值。主要研究包括對製造外包及其客戶群的技術負責人、品質主管、供應鏈經理和研發主管進行結構化訪談。這些訪談提供了關於能力投資、商業重點以及監管和貿易發展對其營運影響的第一手資訊。次要研究則利用監管指南、專利申請、臨床試驗註冊資訊和開放原始碼企業資料，整合觀察到的趨勢並識別能力佈局的變化。

數據綜合採用了三角驗證法，將定性見解與已記錄的監管行動和觀察到的能力投資進行匹配。分析框架包括能力映射、供應鏈脆弱性評估和合作夥伴原型構建，從而能夠將分散的訊號轉化為連貫的策略意義。品管包括專家同儕審查、調查方法（審核確保研究結果的可重複性）以及敏感性檢查（以評估結論對其他解釋的穩健性）。在整個研究過程中，重點在於產生反映營運實際情況和監管限制的可操作情報，同時保持資料來源和得出建議的推理步驟的透明度。

對口服固體製劑生產中的戰略要務、風險考量以及投資和營運調整的優先領域進行總結性綜合分析

這份高階主管總結報告重點闡述了口服固體製劑契約製造領域相關人員面臨的幾項共同要務。技術差異化、營運靈活性和供應鏈韌性將日益決定哪些供應商能夠贏得戰略契約，哪些客戶能夠獲得可靠的供應。隨著連續生產、數位化品質系統和先進製劑技術從早期採用者發展成為行業標準，受託製造製造商的價值提案取決於其能否將這些能力整合到一個連貫的、面向客戶的服務模式中。監管機構對可追溯性和即時品質保證的要求進一步推動了戰略要務，因此需要投資於能夠支援合規性和營運改進的數據系統。

對於決策者而言，未來發展之路需要在選擇性資本配置和夥伴關係驅動型創新之間取得平衡。投資模組化製造和相關開發服務可以增強選擇餘地，而加強籌資策略和地理多元化則可以降低關稅和物流風險。最終，那些能夠將卓越的技術和諮詢能力相結合，幫助客戶將配方科學轉化為可擴展且符合監管要求的生產模式的企業，將最有可能贏得長期夥伴關係關係。本競爭考察摘要旨在為採購、營運、監管事務和業務拓展等領域提供切實可行的後續步驟，並為將結構性趨勢轉化為競爭優勢和營運韌性提供藍圖。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 採用連續生產技術加速口服固體製劑的生產並降低批次差異
  • 在契約製造工廠實施先進的數位雙胞胎和即時製程分析技術（PAT）監控，以提高品管。
  • 為滿足個人化醫療的需求，特殊緩釋性和標靶口服固體製劑的需求激增。
  • 擴大外包設施中高活性藥物成分的產能，以滿足腫瘤治療需求
  • 將綠色化學原則和永續輔料採購融入口服固態製劑生產營運中
  • 製藥創新者與合約生產商之間的策略聯盟，旨在共同開發和技術轉移複雜的口服固體製劑
  • 監管機構對序列化和可追溯性合規性的重視，正在推動對智慧包裝解決方案的投資。
  • 發展自動化端到端連續製粒和壓片系統以提高生產效率
  • 兒科和孤兒藥口服固體製劑需求的不斷成長，催生了對專業契約製造服務的需求。
  • 投資於數位化供應鏈韌性和替代採購管道，以減輕疫情後固態口服製劑供應中斷的影響

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 口服固態契約製造市場（依劑型分類）

  • 膠囊
    • 硬明膠
    • 軟明膠
  • 顆粒
    • 即時發布
    • 修復版本
  • 顆粒
    • 包衣顆粒
    • 多粒子
  • 藥片
    • 塗層
    • 未塗層

9. 依治療領域分類的口服固態契約製造市場

  • 抗感染藥物
    • 抗生素
    • 抗病毒藥物
  • 心血管系統
    • 高血脂症
    • 高血壓
  • 中樞神經系統
    • 憂鬱症
    • 癲癇
  • 消化器官系統
    • 制酸劑
    • 促動力藥
  • 腫瘤學
    • 血液學
    • 固態腫瘤

第10章 依應用分類的口服固態製劑契約製造市場

  • 在商店
  • 處方藥

第11章 口服固態契約製造市場（依階段分類）

  • 臨床試驗
  • 商業的

第12章 依客戶類型分類的口服固態契約製造市場

  • 生物技術
  • 營養補充品
  • 製藥

第13章：各地區口服固態製劑契約製造市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 口服固態製劑契約製造市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國口服固態製劑契約製造市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Catalent, Inc.
    • Thermo Fisher Scientific Inc.
    • Lonza Group AG
    • Recipharm AB
    • Siegfried Holding AG
    • Fareva SA
    • PCI Pharma Services, Inc.
    • Aurobindo Pharma Limited
    • Ajinomoto Bio-Pharma Services, LLC
    • Piramal Pharma Limited
Product Code: MRR-0D217D5AE60A

The Oral Solid Dosage Contract Manufacturing Market is projected to grow by USD 87.70 billion at a CAGR of 8.95% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 44.16 billion
Estimated Year [2025] USD 48.20 billion
Forecast Year [2032] USD 87.70 billion
CAGR (%) 8.95%

A concise but comprehensive introduction that frames the current dynamics shaping oral solid dosage contract manufacturing and strategic relevance to stakeholders

The oral solid dosage contract manufacturing sector sits at the intersection of pharmaceutical innovation, complex supply chains, and stringent regulatory regimes, requiring stakeholders to balance agility with uncompromising quality. This executive summary introduces the landscape by outlining the structural drivers that dictate capacity planning, formulation strategy, and partner selection, and by framing the competitive tensions between speed-to-market and long-term operational resilience. As development pipelines broaden and customer needs diversify, contract manufacturers are transitioning from pure production partners to strategic collaborators who contribute formulation expertise, regulatory know-how, and lifecycle management support.

Understanding the forces at play requires a clear view of how product form and therapeutic focus inform manufacturing complexity, how clinical and commercial stages alter demand patterns, and how customer types-ranging from biotechnology innovators to established pharmaceutical companies and nutraceutical producers-shape service expectations. This introduction establishes the analytical lens used throughout the report: one that integrates technical capability assessment with commercial strategy and supply chain risk management. It also highlights the imperative for decision-makers to adopt an evidence-based approach to outsourcing that weighs the benefits of specialization against the vulnerabilities introduced by concentrated supplier networks and evolving trade policies. The remainder of this executive summary translates these observations into actionable insights for procurement, operations, regulatory affairs, and business development leaders.

An analysis of transformative technological, regulatory, and supply chain shifts redefining capacity, quality expectations, and partnership models in contract manufacturing

The contract manufacturing landscape for oral solid dosage forms is undergoing a series of transformative shifts driven by converging technological advances, regulatory expectations, and changing client demands. Continuous manufacturing and advanced process control systems are maturing from pilot demonstrations into validated production routes, enabling improved throughput and tighter control of critical quality attributes. At the same time, digitalization of manufacturing operations-covering electronic batch records, predictive maintenance, and advanced analytics-reshapes how capacity is monitored, deviations are managed, and regulatory evidence is compiled. These technology-enabled improvements are leading to new partnership models in which manufacturers offer integrated development and scale-up services rather than discrete batch production slots.

Regulatory frameworks are also evolving, with agencies prioritizing real-time product quality assurance and lifecycle data that demonstrate robustness and traceability. This regulatory emphasis increases the value of integrated data ecosystems and strengthens the negotiating position of manufacturers that can demonstrate end-to-end quality controls. Moreover, the rise of complex formulations and multiparticulate technologies adds technical differentiation to service offerings, pushing contract manufacturers to invest selectively in specialized capabilities. Concurrently, customer expectations are shifting: biotechnology firms seek nimble, development-focused partners; large pharmaceutical companies prioritize long-term, compliant suppliers with proven global distribution capabilities; and nutraceutical customers emphasize cost efficiency and rapid market access. The interaction of these factors is prompting a redefinition of what it means to be a strategic contract manufacturing partner and is accelerating consolidation, capability specialization, and collaborative commercialization models.

An assessment of the cumulative effects of United States tariff policy changes in 2025 on sourcing, cost structures, supply chain resilience, and strategic sourcing choices

The 2025 tariff environment introduced by the United States has produced layered implications across sourcing choices, unit cost structures, and contingency planning for contract manufacturing of oral solid dosage forms. Tariff adjustments have affected the cost competitiveness of importing intermediate excipients, active pharmaceutical ingredients, and certain capital equipment, prompting many manufacturers and their customers to reassess supplier footprints and inventory strategies. For some organizations, the immediate response has been to diversify procurement channels, build inventory cushions for critical raw materials, and evaluate nearshoring or reshoring alternatives to reduce exposure to cross-border cost volatility. These tactical moves, however, entail trade-offs between working capital intensity and supply chain flexibility.

Beyond procurement, tariff-induced input cost variability is influencing upstream decisions in formulation development and process selection. Teams are increasingly favoring formulations and excipient sets that minimize exposure to tariff-sensitive components or that permit substitution without compromising stability or performance. In parallel, contract manufacturers are investing in supply chain mapping and dual-sourcing strategies to mitigate single-point-of-failure risks. The tariffs also elevate the strategic importance of logistics optimization, classification accuracy, and free trade zone utilization as levers to manage landed costs. Looking forward, operational resilience will depend less on single cost advantages and more on the ability to integrate procurement agility, regulatory compliance for material substitutions, and transparent supplier relationships into a coherent risk-mitigation posture.

Segment-driven insights revealing how form, therapeutic focus, application, development stage, and customer type influence service demands across contract manufacturing operations

Segment-level dynamics are central to understanding demand drivers and capability requirements across oral solid dosage contract manufacturing. When form type considerations are front and center, capsules present distinct supply chain and tooling requirements compared to tablets; capsules can be segmented into hard gelatin and soft gelatin variants, while granules carry immediate release and modified release considerations, pellets require coated pellet or multiparticulate expertise, and tablets demand differentiated approaches for coated and uncoated configurations. These form-specific factors determine equipment investments, analytical testing scope, and stability program complexity, and they influence which providers are suited to development versus high-volume commercial work.

Therapeutic area focus further shapes service profiles, with anti-infective programs spanning antibiotics and antivirals that often emphasize rapid scale-up and stringent potency controls, and cardiovascular portfolios addressing hyperlipidemia and hypertension with long-term release and high-stability demands. Central nervous system therapies bring requirements for low-dose precision and controlled-release depression or epilepsy formulations, while gastrointestinal treatments such as acid reducers and prokinetics impose unique dissolution and biopharmaceutic considerations. Oncology work, whether hematological or solid tumor-directed, requires specialized containment, chain-of-custody processes, and patient-safety-focused quality systems. Application orientation-over-the-counter versus prescription-affects regulatory pathways, labeling, and shelf-life expectations, and the distinction between clinical trial-stage and commercial-stage projects determines the balance between flexibility and validated repeatability. Finally, customer type influences engagement models: biotechnology companies often require bespoke development support and agility, nutraceutical clients prioritize cost-efficient production and rapid time-to-shelf, and pharmaceutical customers emphasize long-term supply reliability and global regulatory harmonization. Taken together, these segmentation dimensions provide a framework for aligning technical investments, commercial positioning, and partnership design to client-specific needs.

Regional strategic outlook describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics are reshaping manufacturing footprints, logistics, and regulatory navigation

Regional dynamics vary considerably and shape strategic choices for manufacturing footprint, regulatory strategy, and logistics. In the Americas, manufacturers benefit from proximity to large commercial markets and rapid-response distribution networks, but they also face stringent regulatory scrutiny and competitive pressure to localize production for certain product classes. This region is often chosen for late-stage commercial supply and for programs where time-to-market and rapid replenishment capabilities are critical, and it supports models that emphasize validated large-scale capacity and advanced quality systems.

Europe, Middle East & Africa present a multifaceted environment in which regulatory heterogeneity and fragmented pricing landscapes require sophisticated regulatory intelligence and flexible distribution planning. Manufacturers operating in this region must navigate diverse approval pathways, varying regulatory timelines, and regional trade agreements that influence where clinical and commercial batches are produced. Capability investments here often include modular facilities and robust pharmacovigilance infrastructures to support multinational launches and post-approval commitments.

Asia-Pacific remains a strategic hub for both development-stage work and volume manufacturing, offering extensive capabilities in formulation development, cost-competitive production, and rapidly expanding analytical and regulatory expertise. However, companies in this region must balance cost advantages with growing expectations around quality assurance, data integrity, and compliance with international regulatory standards. Supply chain resilience considerations, including port capacities and geopolitical risks, play a prominent role in regional sourcing decisions and in choices about inventory positioning for global programs.

Competitive intelligence summarizing the strategic priorities, capability investments, and partnership approaches that distinguish leading contract manufacturing organizations

Leading contract manufacturers distinguish themselves through a combination of deep technical capabilities, integrated development services, and demonstrated regulatory track records. Top-tier providers invest selectively in flexible production platforms that can be validated across a range of solid dosage forms while maintaining rigorous data integrity and quality assurance systems. They commonly pair capacity investments with adjacent services such as formulation optimization, analytical method development, and stability sciences, enabling clients to transition smoothly from clinical batches to commercial throughput without redundant vendor handoffs.

Another characteristic of high-performing firms is a clear articulation of partnership models that align incentives with client success. This includes transparent cost structures, shared risk arrangements for scale-up, and value-added services such as regulatory dossier support and serialization readiness. Investments in digital operations-real-time batch analytics, integrated quality management systems, and advanced supply chain visibility tools-also segregate leaders from commodity providers. Additionally, firms that cultivate robust supplier ecosystems for excipients, packaging, and specialized tooling are better positioned to manage disruptions and offer reliable lead times. Strategic M&A and alliance activity continue to be vehicles for capability expansion, but the most consequential competitive differentiators remain the ability to deliver predictable quality at scale, to innovate around formulation challenges, and to provide consultative support across product lifecycles.

Actionable recommendations for industry leaders to accelerate resilience, drive efficiency, capture new opportunities, and align operations with evolving customer and regulatory needs

Industry leaders can purposefully translate insight into action by adopting a set of targeted operational and commercial priorities. First, invest in modular, flexible manufacturing platforms that support rapid changeover between capsules, granules, pellets, and tablet production while preserving validated quality controls; this approach lowers barrier-to-entry for diverse programs and accelerates response to shifting client pipelines. Concurrently, strengthen formulation and analytical services to support complex therapeutic areas, from low-dose CNS products to oncology formulations requiring specialized containment and stability protocols. These capabilities reduce time-to-scale and increase the attractiveness of a provider for long-term partnerships.

Second, embed supply chain resilience into procurement and planning by instituting dual-sourcing strategies for critical excipients and leveraging near-term inventory strategies for tariff-sensitive inputs. Augment this with advanced procurement analytics and supplier performance monitoring to detect and remediate vulnerabilities early. Third, prioritize regulatory and data integrity investments that facilitate multinational submissions and real-time quality monitoring, including expanded capabilities for electronic batch records, serialization, and regulatory dossier compilation. Fourth, refine commercial offerings to include outcome-based partnership models and bundled development-to-commercial transition services that align incentives and reduce client friction. Finally, cultivate a digital transformation roadmap that links production analytics, predictive maintenance, and quality metrics to executive dashboards; this enables faster decision cycles, clearer capacity signaling, and demonstrable compliance during audits.

Robust research methodology detailing primary and secondary data collection, expert validation, quality controls, and analytical frameworks used to ensure rigorous insights and reproducibility

The research approach underpinning this executive summary integrates multiple data streams and validation protocols to ensure analytical rigor and practical relevance. Primary research included structured interviews with technical leaders, quality heads, supply chain managers, and business development executives across contract manufacturers and their customer base. These discussions provided first-hand perspectives on capability investments, commercial priorities, and the operational impacts of regulatory and trade developments. Secondary research drew on public regulatory guidance, patent filings, clinical trial registries, and open-source corporate disclosures to contextualize observed trends and identify shifts in capability footprints.

Data synthesis employed triangulation techniques that cross-checked qualitative insights with documented regulatory actions and observed capacity investments. Analytical frameworks included capability mapping, supply chain vulnerability assessment, and partner archetype development, which together enabled the translation of disparate signals into coherent strategic implications. Quality controls involved peer review by subject-matter experts, methodology audits to verify reproducibility of findings, and sensitivity checks to assess the robustness of conclusions against alternative interpretations. Throughout the research process, emphasis was placed on producing actionable intelligence that reflects operational realities and regulatory constraints while maintaining transparency about data sources and the inferential steps taken to derive recommendations.

Concluding synthesis that crystallizes strategic imperatives, risk considerations, and priority areas for investment and operational adaptation in oral solid dosage manufacturing

This executive synthesis highlights several convergent imperatives for stakeholders in oral solid dosage contract manufacturing. Technical differentiation, operational flexibility, and supply chain resilience will increasingly determine which providers win strategic engagements and which clients secure dependable supply. As continuous manufacturing, digital quality systems, and advanced formulation capabilities migrate from early adopters to industry norms, the value proposition of contract manufacturers will rest on the ability to integrate these capabilities into coherent, client-facing service models. Regulatory demands for traceability and real-time quality assurance add another layer of strategic necessity, requiring investment in data systems that support both compliance and operational improvement.

For decision-makers, the path forward requires balancing selective capital allocation with partnership innovation. Investing in modular production and adjacent development services builds optionality, while enhanced procurement strategies and geographic diversification mitigate tariff and logistics risks. Ultimately, organizations that combine technical excellence with consultative engagement-helping clients translate formulation science into scalable, regulatorily defensible production-will be best positioned to capture long-term partnerships. The insights in this summary aim to inform pragmatic next steps across procurement, operations, regulatory affairs, and business development, offering a roadmap for converting structural trends into competitive advantage and operational resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of continuous manufacturing technologies to accelerate oral solid dosage production and reduce batch variability
  • 5.2. Implementation of advanced digital twins and real-time PAT monitoring in contract manufacturing facilities for improved quality control
  • 5.3. Surge in specialty modified-release and targeted oral solid dosage formulations to meet personalized medicine demands
  • 5.4. Expansion of high-potency active pharmaceutical ingredient handling capabilities in outsourcing facilities to address oncology therapies
  • 5.5. Integration of green chemistry principles and sustainable excipient sourcing in oral solid dosage manufacturing operations
  • 5.6. Strategic alliances between pharma innovators and CMOs for co-development and tech transfer of complex OSD formulations
  • 5.7. Regulatory emphasis on serialization and track-and-trace compliance driving investment in smart packaging solutions
  • 5.8. Growth of automated end-to-end continuous granulation and tableting systems to enhance production efficiency
  • 5.9. Rising demand for pediatric and orphan drug oral solid formulations prompting specialized contract manufacturing services
  • 5.10. Investments in digital supply chain resilience and alternative sourcing to mitigate post-pandemic oral solid dosage disruptions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Solid Dosage Contract Manufacturing Market, by Form Type

  • 8.1. Capsules
    • 8.1.1. Hard Gelatin
    • 8.1.2. Soft Gelatin
  • 8.2. Granules
    • 8.2.1. Immediate Release
    • 8.2.2. Modified Release
  • 8.3. Pellets
    • 8.3.1. Coated Pellets
    • 8.3.2. Multiparticulate
  • 8.4. Tablets
    • 8.4.1. Coated
    • 8.4.2. Uncoated

9. Oral Solid Dosage Contract Manufacturing Market, by Therapeutic Area

  • 9.1. Anti Infectives
    • 9.1.1. Antibiotics
    • 9.1.2. Antivirals
  • 9.2. Cardiovascular
    • 9.2.1. Hyperlipidemia
    • 9.2.2. Hypertension
  • 9.3. Central Nervous System
    • 9.3.1. Depression
    • 9.3.2. Epilepsy
  • 9.4. Gastrointestinal
    • 9.4.1. Acid Reducers
    • 9.4.2. Prokinetics
  • 9.5. Oncology
    • 9.5.1. Hematological
    • 9.5.2. Solid Tumor

10. Oral Solid Dosage Contract Manufacturing Market, by Application

  • 10.1. Over The Counter
  • 10.2. Prescription Drugs

11. Oral Solid Dosage Contract Manufacturing Market, by Stage

  • 11.1. Clinical Trial
  • 11.2. Commercial

12. Oral Solid Dosage Contract Manufacturing Market, by Customer Type

  • 12.1. Biotechnology
  • 12.2. Nutraceutical
  • 12.3. Pharmaceutical

13. Oral Solid Dosage Contract Manufacturing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Solid Dosage Contract Manufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Solid Dosage Contract Manufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Catalent, Inc.
    • 16.3.2. Thermo Fisher Scientific Inc.
    • 16.3.3. Lonza Group AG
    • 16.3.4. Recipharm AB
    • 16.3.5. Siegfried Holding AG
    • 16.3.6. Fareva SA
    • 16.3.7. PCI Pharma Services, Inc.
    • 16.3.8. Aurobindo Pharma Limited
    • 16.3.9. Ajinomoto Bio-Pharma Services, LLC
    • 16.3.10. Piramal Pharma Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFA